Request Deal Involvement
SOBI completed the acquisition of the emapalumab business from Novimmune for $519m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Lenz & Staehelin
legal advisors
Walder Wyss
legal advisors
Bar & Karrer
debt providers
BNP Paribas
debt providers
Danske Bank
debt providers
SEB Corporate Finance
debt providers
Handelsbanken Capital Markets
or
Principals
vendor
NOVIMMUNE
bidder
SWEDISH ORPHAN BIOVITRUM AB (SOBI)
target
NOVIMMUNE (EMAPALUMAB AND RELATED ASSETS)
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite